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Maternal caffeine intake during pregnancy and risk of fetal
growth restriction: a large prospective observational study
CARE Study Group
ABSTRACT
Objective To examine the association ofmaternal caffeine
intake with fetal growth restriction.
Design Prospective longitudinal observational study.
Setting Two large UK hospital maternity units.
Participants 2635 low risk pregnant women recruited
between 8-12 weeks of pregnancy.
Investigations Quantification of total caffeine intake from
4weeksbeforeconceptionand throughoutpregnancywas
undertaken with a validated caffeine assessment tool.
Caffeine half life (proxy for clearance) was determined by
measuring caffeine in saliva after a caffeine challenge.
Smoking and alcohol were assessed by self reported
status and bymeasuring salivary cotinine concentrations.
Main outcome measures Fetal growth restriction, as
defined by customised birth weight centile, adjusted for
alcohol intake and salivary cotinine concentrations.
Results Caffeine consumption throughout pregnancy was
associated with an increased risk of fetal growth restriction
(odds ratios 1.2 (95% CI 0.9 to 1.6) for 100-199 mg/day,
1.5 (1.1 to 2.1) for 200-299 mg/day, and 1.4 (1.0 to 2.0)
for >300mg/day comparedwith <100mg/day; test for trend
P<0.001).Mean caffeine consumption decreased in the first
trimester and increased in the third. The association
betweencaffeineandfetalgrowthrestrictionwasstronger in
women with a faster compared to a slower caffeine
clearance (test for interaction, P=0.06).
Conclusions Caffeine consumption during pregnancy was
associated with an increased risk of fetal growth
restriction and this association continued throughout
pregnancy. Sensible advice would be to reduce caffeine
intake before conception and throughout pregnancy.
INTRODUCTION
Caffeine is the most widely consumed xenobiotic in
pregnancy, with the potential to adversely affect the
developing fetoplacental unit. Maternal caffeine intake
has been reported to be associated with a reduction in
birth weight,1-5 but the precise level of intake above
which the risk is increased remains unknown. Caffeine
intake of ≥300 mg/day has been associated with fetal
growth restriction,6-8 butVlajinac et al founda significant
reduction in infant birth weight of 114 g with maternal
caffeine consumption of as little as 141 mg/day.9 More
controversially, others have shown that maternal
caffeine concentration has an inverse association with
birth weight when confounders such as smoking were
taken into account.21011 In 2001 the Committee on
Toxicity of Chemicals in Food, UK, after a thorough
reviewof the literature, concluded that, althoughcaffeine
intake >300 mg/day might be associated with low birth
weight and spontaneous miscarriage, the evidence was
inconclusive.12
Possible reasons for these inconsistent outcomes
include inaccurate estimation of caffeine consumption,
includinganassumption that tea andcoffee are theonly
sources of caffeine,3 9 10 retrospective assessment of
caffeine intake,2 10 13-15 assessment of association based
on consumption in individual trimesters rather than
throughout pregnancy,4 9 10 13 failure to allow for
individual variations in caffeine metabolism,416 inade-
quate control for confounding factors such as smoking
and alcohol consumption,17 18 and non-uniformity in
defining the primary outcome measures.1 2 4 6 9 10 15 16
Caffeine is rapidly absorbed and crosses the placenta
freely.19 After ingestion of 200 mg caffeine, intervillous
blood flow in the placenta was found to be reduced by
25%.20 Cytochrome P450 1A2, the principal enzyme
involved in caffeinemetabolism, is absent in theplacenta
and the fetus.21 The amount of caffeine and metabolites
available to the fetoplacental unit therefore depends on
the maternal caffeine metabolism, which shows marked
variation between individuals because of genetic and
environmental factors such as nicotine.22-24 Variations in
caffeine metabolic activity have been found to be more
closely associatedwith fetal growth restriction than have
blood caffeine concentrations.25 Therefore, any compre-
hensive study of the effects of caffeine on fetal growth
must include an assessment of caffeine metabolism.
In order to examine the association of maternal
caffeine intake on fetal growth, we used a validated,
robust caffeine assessment tool to quantify total caffeine
intake, from all possible sources, throughout
pregnancy.26 Using these data, and taking into account
individual variation in caffeinemetabolism,we aimed to
establish the safe upper limit of caffeine consumption
with respect to adverse pregnancy outcome (specifically
fetal growth restriction).
METHODS
Participants
We prospectively recruited low risk pregnant women
from two large UK teaching hospital maternity units
(Leeds and Leicester) from September 2003 to June
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2006. The inclusion criteria included age 18-45 years
and singleton pregnancies accurately dated by ultra-
sound. Women with concurrent medical disorders,
psychiatric illness, HIV infection, or hepatitis B
infection were excluded. We identified eligible
women by screening their pre-booking maternity
notes, then sent them detailed information about the
study and asked them to return a reply slip about their
willingness to take part in the study. Personal contacts
were then made with those who agreed to participate.
This initial visit was conducted at the hospital or at the
volunteer’s general practice or home by a clinical
research fellow (Leicester) or a midwife (Leicester and
Leeds) at 8-12 weeks gestation. Volunteers’ demo-
graphic details (age, parity, maternal height, weight,
socioeconomic status, and gestational age) were
recorded by means of a questionnaire.
Quantification of caffeine intake
Caffeine intake was estimated with a validated caffeine
assessment tool, a questionnaire designed at the
University of Leeds, to record habitual caffeine intake
before and during pregnancy.26 Information in the
questionnaire included estimates of caffeine content
from all potential dietary sources and over the counter
drugs and details of potential confounders such as
smoking, alcohol intake, and nausea. We recorded
specific brand names, portion sizes, methods of
preparation, and quantity and frequency of intake for
different gestational periods. We also obtained details
of caffeine content for each item from published
reports,27 manufacturers, and coffee houses, and,
from these, we estimated precise caffeine intakes
using an SPSSv14 program developed in-house.26
Three caffeine assessment tools were administered by
the clinical research fellow and research midwives to
determine caffeine intake in pregnancy—the first,
administered at recruitment by the researcher,
included aspects of recall of caffeine intake from four
weeks before pregnancy until recruitment into the
study at 8-12 weeks of pregnancy; the second covered
the period 13-28 weeks; and the third included the
period 29-40 weeks of pregnancy.
Saliva sample collection, storage, and transport
Saliva samples for determining nicotine exposure
(defined as baseline values before the caffeine chal-
lenge) were collected from women at recruitment,
using a Salivette (Sarstedt, Aktiengesellschaft, Lough-
borough, UK) kept in the mouth for 5-10 minutes.
Additionally, we assessed caffeine half life from a
caffeine challenge test (adapted from Butler et al28)
performed within two weeks of recruitment. We
provided participants with appropriate materials and
instructions to perform the test at home, and the
sampleswere then returned in a prepaid envelope. The
test involved overnight fasting, followed by the
challenge (a drink of 500 ml diet cola containing
63.5 mg caffeine ingested over a period of 20 minutes)
with no other caffeine consumed during the challenge.
Participants then collected saliva samples about one
and five hours after the challenge. Precise sample
collection times anddetails of drinks or food consumed
during the test period were recorded on a question-
naire. When samples arrived at the laboratory, saliva
was isolated from the Salivettes by centrifugation and
stored at −80°C.
Biochemical analyses
All samples were analysed in the Molecular Epide-
miology Unit (University of Leeds).
Salivary caffeine—Salivary caffeine was extracted and
quantified using liquid:liquid extraction and reversed
phase high performance liquid chromatography
(HPLC) with ultraviolet detection.26 We calculated
the half life for caffeine from salivary caffeine
concentrations recorded at one and five hours after
the caffeine challenge.
Table 1 | Demographic and clinical characteristics of 2635 pregnant women and their babies,
according to pregnancy outcome. Values are numbers (percentages) unless stated otherwise
Pregnancy outcome
Fetal growth
restriction (n=343)
Appropriate fetal
growth (n=2292)
Total
(n=2635)
Maternal characteristics
Mean (SD) age (years) 30.0 (6.6) 29.8 (6.5) 30 (6.6)
Mean (SD) weight before pregnancy (kg) 66.7 (13.2) 66.8 (12.6) 66.8 (13.1)
Mean (SD) body mass index before
pregnancy (kg/m2)
24.5 (4.5) 24.5 (4.6) 24.5 (4.5)
Primiparous 186 (55) 1042 (46) 1228 (47)
Preterm labour 29 (8) 77 (3) 106 (4)
Gestational hypertension or pre-
eclampsia
25 (7) 42 (2) 67 (3)
Stillbirth 3 (0.9) 6 (0.3) 9 (0.3)
Late miscarriage 3 (0.9) 16 (0.7) 19 (0.7)
Neonatal characteristics
Mean (SD) gestational age at delivery
(weeks)
40 (3) 40 (2) 40 (2)
Mean (SD) birth weight (g) 2750 (520) 3560 (470) 3450 (550)
Male 172 (50) 1152 (52) 1324 (51)
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Fig 1 | Relation between risk of fetal growth restriction and
caffeine intake (mg/day) during pregnancy. The relation is
modelled by the best-fitting second-order fractional
polynomial, with 95% confidence intervals. The graph is
restricted to <500 mg/day for clarity. Horizontal dotted lines
mark national average risk of fetal growth restriction (10%)
and average risk in study cohort (13%)
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Salivary cotinine—Salivary cotinine concentrations in
samples taken at recruitmentwere quantified bymeans
of enzyme linked immunosorbent assay (ELISA)
(Cozart Bioscience, Oxfordshire, UK) according to
the manufacturer’s instructions. We then classified
participants on the basis of these cotinine concentra-
tions as active smokers (>5 ng/ml), passive smokers
(1-5 ng/ml), or non-smokers (<1 ng/ml).29
Pregnancy outcomes
We obtained information on antenatal pregnancy
complications and delivery details (gestational age at
delivery, birth weight, and sex of the baby) from the
electronic maternity databases.
The primary outcome measure was fetal growth
restriction defined as birth weight <10th centile on a
customised centile chart which takes into account
maternal height, weight, ethnicity, and parity and
neonatal birth weight and sex (www.gestation.net).30
We chose this definition as it is the most commonly
usedandbecause, althoughnot all those cases classified
as fetal growth restriction would be pathological, it is
likely to include most pathological fetal growth
restrictions. In addition, we assessed the association
of maternal caffeine intake with birth weight.
Other pregnancy outcomes studied were late
miscarriage (spontaneous pregnancy loss between
12 and 24 weeks), preterm delivery (delivery at
<37 completed weeks), gestational hypertension
(blood pressure ≥140/90 mmHg on more than one
occasion 4 hours apart after >20 weeks of pregnancy),
proteinuric hypertension (gestational hypertension
and proteinuria of ≥300 mg protein in 24 hours,
based on the International Society for the Study of
Hypertension in Pregnancy31), and stillbirth (delivery
≥24 weeks with no signs of life at birth).
Statistical methods
We expressed participants’ caffeine consumption in
mg/dayaveragedover thewholepregnancyand for the
individual trimesters. To estimate the sample size
required, we assumed that the mean caffeine intake
during pregnancy was 206 mg/day,4 and that caffeine
followed a log normal distribution, with a coefficient of
variationof 1.Assuming that 10%ofbirths showed fetal
growth restriction, then 3000 births would give 80%
power to detect a difference of 30 mg/day in caffeine
intakes between mothers of babies with restricted fetal
growth andmothers of babies of appropriateweight for
gestational age with type I error set at 0.05. This also
gave 80%power to detect an odds ratio for fetal growth
restriction of 1.4 between high and low caffeine
consumers (defined as being above or below the
median caffeine intake).
We performed unconditional logistic regression
modelling for fetal growth restriction and general
linearmodelling for birth weight, with stratification for
the two maternity units, using Stata version 10 survey
facilities.32 Maternal height, weight, ethnicity, and
parity at booking and neonatal gestation at delivery
and sex were taken into account in the definition for
fetal growth restriction, and were adjusted for in the
model for birth weight. We also made statistical
adjustment for salivary cotinine levels and self reported
alcohol consumption in all models. We conducted
sensitivity analyses to assess the robustness of the
results to adjustment for nausea, exclusion of high risk
pregnancies, multiparity, extremely high or low
caffeine intakes, and the maternity unit.
We also assessed the relationbetween the risk of fetal
growth restriction and maternal caffeine intake during
pregnancy by considering caffeine intake as a contin-
uous variable: after adjusting for the factorsmentioned
above, we performed modelling using the best fitting,
second order, fractional polynomial with 95%
confidence intervals.
Caffeinehalf life as assessedby the caffeine challenge
test was not normally distributed. We therefore
categorised women in relation to the median value as
having a shorter half life (faster caffeine clearance from
the circulation) or longer half life (slower clearance).
We stratified the odds ratio for fetal growth restriction
by caffeine half life (as a proxy for clearance) and intake
after taking account of maternal age, weight, height,
ethnicity, and parity and neonatal gestation and sex
and adjusting for smoking status, amount smoked
(cotinine concentration), and alcohol intake.
RESULTS
Over a period of three years, 13071 eligible women
were invited to participate from the two maternity
Table 2 | Mean caffeine and alcohol intake and smoking status among 2635 pregnant women
according to pregnancy outcome. Values are numbers (percentages) unless stated otherwise
Characteristic
Pregnancy outcome
Fetal growth
restriction (n=343)
Appropriate fetal
growth (n=2292)
Total
(n=2635)
Mean (SD) caffeine intake (mg/day):
Throughout pregnancy 200 (202) 153 (145) 159 (154)
First trimester 201 (206) 157 (160) 163 (167)
Second trimester 184 (207) 141 (144) 147 (156)
Third trimester 197 (222) 143 (146) 153 (164)
Caffeine intake during pregnancy:
<100 mg/day 122 (36) 1000 (46) 1122 (44)
100-199 mg/day 90 (27) 601 (27) 691 (27)
200-299 mg/day 63 (19) 313 (14) 376 (15)
≥300 mg/day 63 (19) 284 (13) 347 (14)
Mean (SD) alcohol intake (units/
day):
Throughout pregnancy 0.4 (0.7) 0.4 (0.5) 0.4 (0.6)
First trimester 0.6 (0.9) 0.4 (0.7) 0.5 (0.8)
Second trimester 0.2 (0.4) 0.2 (0.5) 0.2 (0.5)
Third trimester 0.3(0.4) 0.2 (0.5) 0.3 (0.5)
Smoking status (n=2509)*:
Non-smoker 213 (64) 1622 (75) 1835 (73)
Passive smoker 39 (12) 268 (12) 307 (12)
Current smoker 79 (24) 288 (13) 367 (15)
*Smoking status based on salivary cotinine concentrations: non-smoker <1 ng/ml, passive smoker 1-5 ng/ml,
current smoker >5 ng/ml.
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units, and 2635 (20%) consented. Table 1 shows the
demographic and clinical characteristics of the study
population. The prevalence of fetal growth restriction
in the cohort was 343/2635 (13%). The mean alcohol
intake during pregnancy was 0.4 (95% confidence
interval 0 to 9) units/day,with thehighest consumption
occurring, as might be expected, before conception
and during the first four weeks of pregnancy.
Caffeine intake during pregnancy
The women’s mean caffeine intake during pregnancy
was 159 mg/day (table 2). It decreased from
238mg/day before pregnancy to 139mg/day between
weeks 5 and 12 of pregnancy and remained at about
this level until the third trimester, when it gradually
increased to 153 mg/day. About 62% of the caffeine
ingestedby thewomenduringpregnancywas from tea.
Other important sourceswere coffee (14%), cola drinks
(12%), chocolate (8%), and soft drinks (2%). Hot
chocolate, energy drinks, and alcoholic drinks con-
tributed 2%, 1%, and <1% respectively. Over the
counter drugs made a negligible contribution to the
total caffeine intake.
Relation between caffeine intake in pregnancy and fetal
growth
The relation between total caffeine intake in pregnancy
and fetal growth restriction showed a significant trend
with increasing caffeine intake (test for trend P=0.02,
table 3). Compared with caffeine intake of <100 mg/
day, the odds ratio of having a growth restricted baby
increased to 1.2 (95% confidence interval 0.9 to 1.6) for
intakes of 100-199mg/day, to 1.5 (1.1 to 2.1) for intakes
of 200-299mg/day, and to 1.4 (1.0 to 2.0) for intakes of
≥300 mg/day. This relation was consistent across all
three trimesters.
Caffeine consumption of >200 mg/day during
pregnancy was associated with a reduction in birth
weight of about 60-70 g, with a significant trend for
greater reduction in birth weight with higher caffeine
intake (P=0.004). This relationwas consistent across all
three trimesters (table 4).
In a small cohort of women (n=109) who had
reduced their caffeine intake from 300 mg/day before
pregnancy to <50mg/day byweeks 5-12 of pregnancy
their offspring’smeanbirthweightwashigher than that
of those who maintained their caffeine intake at
>300 mg/day (n=193) (difference in birth weight
161 g (95% confidence interval 24 to 297 g), P=0.02).
To examine possible threshold effects, we analysed
the relation between the estimated risk of delivering a
growth restricted fetus and maternal caffeine intake
during pregnancy measured as a continuous variable
(fig 1). There was a rapid increase in associated risk
from increasing caffeine intake up to about 30mg/day.
Thereafter, estimated risk continued to rise roughly
linearly in a dose-response relation. At no point did the
estimated risk cease to increasewith increasing caffeine
intake. There was no observed plateau effect.
Relation between caffeine clearance and fetal growth
Using maternal caffeine half life as a proxy for
clearance rate, we found some evidence that the
association between caffeine intake and fetal growth
restrictionwas stronger in womenwith a faster caffeine
Table 3 | Risk of fetal growth restriction among offspring of 2635 pregnant women according to caffeine intake during pregnancy
Caffeine intake (mg/day)
Unadjusted risk* Adjusted risk†
Odds ratio (95% CI) Test for trend Odds ratio (95% CI) Test for trend
Average over pregnancy:
<100 1
P<0.001
1
P=0.02
100-199 1.2 (0.9 to 1.6) 1.2 (0.9 to 1.6)
200-299 1.6 (1.2 to 2.3) 1.5 (1.1 to 2.1)
≥300 1.8 (1.3 to 2.5) 1.4 (1.0 to 2.0)
In weeks 5-12:
<100 1
P<0.001
1
P=0.05
100-199 1.2 (0.9 to 1.6) 1.1 (0.8 to 1.5)
200-299 1.4 (1.0 to 2.0) 1.3 (0.9 to 1.9)
≥300 1.8 (1.3 to 2.5) 1.4 (1.0 to 1.9)
In weeks 13-28:
<100 1
P=0.001
1
P=0.02
100-199 1.5 (1.1 to 2.0) 1.4 (1.0 to 2.0)
200-299 1.8 (1.3 to 2.6) 1.7 (1.2 to 2.4)
≥300 1.6 (1.1 to 2.4) 1.3 (0.9 to 2.0)
In weeks 29-40:
<100 1
P<0.001
1
P=0.004
100-199 1.4 (1.0 to 1.9) 1.4 (1.0 to 2.0)
200-299 1.9 (1.3 to 2.8) 1.8 (1.2 to 2.7)
≥300 1.9 (1.3 to 2.8) 1.6 (1.0 to 2.4)
*Unadjusted odds ratios take account of maternal age, weight, height, ethnicity, and parity and neonatal gestational age at delivery and sex.
†Adjusted odds ratios are also adjusted for smoking status (salivary cotinine concentration) and alcohol intake.
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clearance than in those with slower clearance (test for
interaction, P=0.06) (table 5).
Relation between smoking in pregnancy and fetal growth
Women classified as active smokers (based on their
salivary cotinine concentrations) had nearly twice the
risk of fetal growth restriction compared with women
classified as non-smokers (adjusted odds ratio 1.9 (95%
confidence interval 1.4 to 2.6), P<0.001). The birth
weights of babies born to active smokers were 178 g
lighter (95% confidence interval 127 to 230 g) than
those born to non-smokers (P<0.001). Adjusting for
nausea (reported by 81% of the population in the first
trimester) did not alter these results.
DISCUSSION
This is one of the largest prospective studies investigat-
ing the associationofmaternal caffeine intakewith fetal
growth. Maternal caffeine intake was associated with
an increased risk of fetal growth restriction even after
adjustment for smoking and alcohol intake. We could
find no level of intake at which therewas no association
with increased risk of fetal growth restriction. The size
of the association for caffeinewasof a similar size to that
for alcohol intake inpregnantwomen in this study (data
not shown).
The strong association between caffeine intake and
birthweightwasmaintained across all of the trimesters.
However, from these results we cannot define a critical
time window for any maximal effect. This clearly
warrants further investigation.
Strengths and weaknesses of the study
Although only 20% of the women we invited took part
in the study, this low response rate does not lessen the
validity of our data, as the association of caffeine with
birth weight should not be different from that in the
general population, especially as various confounders
were taken into consideration. In addition, examina-
tion of our maternity databases indicated that the
population we studied was similar to that of the
maternity units as a whole.
A major strength of our study is that we have
objectively quantified caffeine from all known sources.
Caffeine intake was validated by comparison with a
food diary and repeated measures of exposure from
saliva samples,27 and we believe that, for the first time,
this reflects a true picture of total caffeine intake by
women during pregnancy. More than 60% of the
caffeine consumed was from tea, and only 14% from
coffee. Our findings emphasise the weaknesses of
studies where caffeine intake was equated to that of
coffee alone. Weng et al reported that coffee was the
sole source of caffeine in 19% of their pregnant cohort,
and 44% consumed caffeine from combined caffeine
andnon-caffeine sources.33Since26%of caffeine intake
in our cohort was from neither coffee nor tea, studies
that concentrated on coffee and tea alone would have
grossly underestimated caffeine intake.
Study results in comparison with other studies
Caffeine consumption almost halved in early
pregnancy (from 250 mg/day before pregnancy to
150mg/day in the first trimester), as has been reported
Table 4 | Unadjusted and adjusted linear regression for birth weight among offspring of 2635 pregnant women according to
caffeine intake during pregnancy
Caffeine intake (mg/day)
Unadjusted change in birth weight (g) Adjusted change in birth weight (g)*
Change (95% CI) Test for trend Change (95% CI) Test for trend
Average over pregnancy:
<100 0
P<0.001
0
P=0.004
100-199 −1 (−51 to 50) −21 (−62 to 20)
200-299 −63 (−129 to 4) −70 (−123 to −18)
≥300 −144 (−221 to −66) −63 (−119 to −6)
In weeks 5-12:
<100 0
P<0.001
0
P=0.009
100-199 −6 (−58 to 45) −34 (−76 to 8)
200-299 −66 (−134 to 2) −61 (−112 to −9)
≥300 −144 (−220 to −69) −59 (−114 to −4)
In weeks 13-28:
<100 0
P=0.003
0
P=0.006
100-199 −15 (−74 to 44) −24 (−72 to 24)
200-299 −44 (−119 to 30) −65 (−124 to −6)
≥300 −129 (−212 to 46) −74 (−138 to −10)
In weeks 29-40:
<100 0
P=0.009
0
P=0.004
100-199 −25 (−98 to 48) −66 (−125 to −7)
200-299 −61 (−154 to 31) −69 (−141 to 3)
≥300 −119 (−211 to −27) −89 (−158 to −21)
*Adjusted estimates take account of maternal age, weight, height, ethnicity, parity, smoking status (salivary cotinine concentration), and alcohol
intake and neonatal gestational age at delivery and sex.
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elsewhere.34 The mean caffeine intake throughout
pregnancy was much lower than the limit of 300 mg/
day recommended by the UK government’s Food
Standards Agency12 and in the USA.35
Several studieshaveconcluded that caffeine intakeof
>300 mg/day is associated with low birth weight or
fetal growth restriction.6-8 Our study confirms these
findings and further defines the nature of the associa-
tion.Wecould findno level of intake atwhich therewas
no association with increased risk of fetal growth
restriction, and this risk was maintained throughout
pregnancy. Although the overall size of the reduction
in birthweightmaybe seen as small, an extra 60-70 g in
weight could reduce perinatal morbidity andmortality
in an already compromised fetus. The steep decline in
risk associated with caffeine intakes of <30 mg/day
may be attributable to unmeasured confounding.
Furthermore,womenwhoconsume little or no caffeine
may be generally more health conscious than those
who consume more, and the effect may be one for
which we have been unable to adjust.
We found that average caffeine consumption of
>100 mg/day was associated with a reduction in birth
weight of 34-59 g in the first trimester, 24-74 g in the
second, and 66-89 g in the third (after adjustment for
smoking status andalcohol intake). Similar resultswere
seen by Bracken et al in a prospective study of 2291
pregnant women in the US, where mean birth weight
was reduced by 28 g for every 100 mg/day of caffeine
consumed (P=0.0001), but the risk for fetal growth
restriction was unchanged (odds ratio 0.96).36 This
difference could be explained by methodological
differences in the studies.
A Danish cohort of 1207 women drinking at least
three cups of coffee a daybefore 20weeks of pregnancy
were randomised to receive either caffeinated or
decaffeinated instant coffee: there was no significant
difference in birth weight between the two groups after
adjustment for parity, gestational age at birth, and
smoking.37 However, these women were recruited in
the second half of pregnancy, so the effect of first
trimester caffeine intake was not assessed, and there
was no biochemical confirmation of participants’
compliance with caffeinated or decaffeinated coffee
consumption.
In addition, Bicalho and Filho reported no associa-
tion between maternal caffeine consumption and low
birth weight after adjusting for confounding variables
in a case-control study in Brazil.38
Caffeine metabolism
Some of the variation in previously reported associa-
tions between caffeine intake and pregnancy outcomes
may reflect the effect of differences in caffeine meta-
bolism. The degree to which a fetus is exposed to
caffeine and its metabolites, which pass freely
across the placenta, depends on maternal cytochrome
P450 1A2 (CYP1A2) activity because this enzyme is
absent in the fetus. We complemented our assessment
of caffeine intake with a measure of caffeine meta-
bolism and observed that the association of caffeine
intake with fetal growth restriction was greater among
women with faster caffeine clearance.
Caffeine is primarilymetabolised in the human liver
to paraxanthine,39 but there is little data about meta-
bolism in pregnant women. In our study caffeine was
metabolised to paraxanthine, theobromine, and theo-
phylline, with theobromine present in highest concen-
tration in most of the women. As we were unable to
measure the rate of formation or subsequent meta-
bolism of these primary metabolites, we cannot
attribute the association with fetal growth to any single
metabolite.The associationweobservedmaybedue to
caffeine itself or one of its metabolites, or to any
combination of them.
In a study of pregnant women who smoked,
Klebanoff et al reported a positive association between
maternal paraxanthine concentration in the third
Table 5 | Stratification of risk of fetal growth restriction among offspring of 2635 pregnant
women according to caffeine intake during pregnancy and caffeine half life (proxy for
clearance)
Caffeine intake (mg/day)
Risk of fetal growth restriction*
Odds ratio (95% CI) Test for trend
Shorter caffeine half life (n=774)†
<100 1
P=0.02
100-199 1.6 (0.9 to 3.0)
200-299 2.4 (1.3 to 4.4)
≥300 1.7 (0.9 to 3.3)
Longer caffeine half life (n=764)†
<100 1
P=0.8
100-199 1.1 (0.6 to 1.7)
200-299 0.6 (0.3 to1.3)
≥300 1.5 (0.7 to 2.9)
Test for interaction of half life P=0.06
*Adjusted for maternal age, weight, height, ethnicity, parity, smoking status (salivary cotinine concentration),
and alcohol intake and neonatal gestational age at delivery and sex.
†Shorter caffeine half life (≤median value)=faster clearance; longer half life (>median value)=slower clearance).
WHAT IS ALREADY KNOWN ON THIS TOPIC
Caffeine is the most common xenobiotic consumed in
pregnancy, and there are conflicting results regarding the
association of increased caffeine intake in pregnancy with
fetal growth restriction and low birth weight
These differences could be explained by inconsistencies in
accurate quantification of caffeine and in the definition of
fetal growth restriction
WHAT THIS STUDY ADDS
Maternal caffeine intake isassociatedwithan increased risk
of fetal growth restriction after adjustment for smoking and
alcohol intake
The size of the association for caffeine intake with fetal
growth restriction is similar to that for alcohol intake
The association of caffeine with fetal growth restriction
seemstobestronger inwomenwith fastercaffeineclearance
Sensible advice to pregnant women would be to reduce
caffeine intake before conception and during pregnancy
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trimester and having an infant that was small for its
gestational age.40 In another study, the highest con-
centrations of paraxanthine were associated with an
increased risk of spontaneous abortion.41 Recently,
higher cord blood paraxanthine concentrations have
been shown to be associated with an increased risk of
intrauterine growth restriction after adjustment for
caffeine levels, implying an effect of CYP1A2 activity
rather than absolute levels of paraxanthine.25 Further
consideration of the role of CYP1A2 activity and
caffeine metabolites is clearly warranted.
Conclusion
This large prospective cohort study has demonstrated
that maternal caffeine intake is associated with an
increased risk of fetal growth restriction. The threshold
at which this risk is significantly higher is not well
characterised, but our data confirm that the association
of fetal growth restriction with caffeine is reduced for
those consuming <100 mg/day. We suggest that
sensible advice for women contemplating pregnancy
is to reduce their caffeine intake fromall sources before
conception.Oncepregnancy is confirmed, they should
make every effort to stop or markedly reduce caffeine
consumption.
We thank Gordon Gibson, Fred Kadlubar, and Mark Klebanoff for their
useful comments during the study. The Leicester team of the CARE Study
Group thank Vilas Misty, Clare Lawrence, Bhavin Daudia, and the
Department of Chemical Pathology, University Hospitals of Leicester N
HS Trust, for sample handling and processing.
Members of the CARE Study Group:
Leeds team: Sinead Boylan, Janet E Cade, Vivien A Dolby, Darren
C Greenwood, Alastair W M Hay, Sara F L Kirk, Susan Shires, Nigel
Simpson, James D Thomas, James Walker, Kay L M White, Christopher
P Wild, Centre for Epidemiology and Biostatistics, University of Leeds,
Leeds LS2 9JT
Leicester team: Neelam Potdar, Justin C Konje, Nicholas Taub, Jim Charvill,
Karen C Chipps, Shabira Kassam, Chetan Ghandi, , Marcus S Cooke,
Departments of Cancer Studies and Molecular Medicine and Health
Sciences, University of Leicester, Leicester LE2 7LX
Steering group: Justin C Konje (chair), Marcus Cooke (principal
investigator), Leicester; Janet Cade (principal investigator), Leeds; David
Gott, Natalie Thatcher, Stuart Creton, Caroline Tahourdin, Food Standards
Agency, London; Gordon Gibson, University of Surrey
Statisticians: Darren Greenwood, Leeds; Nicholas Taub, Leicester; Clifton
Gay, Food Standards Agency
Clinicians: Neelam Potdar, Justin C Konje, Leicester; Nigel Simpson, James
Walker, Leeds
Research midwives: Viv Dolby, Heather Ong, Leeds; Shabira Kassam,
Karen Chipps, Leicester
Nutritional methods: Sinead Boyland, Sara Kirk, Janet Cade, Leeds
Laboratory methods: Kay White, Susan Shires, Alastair Hay, Christopher
Wild, Leeds; Marcus Cooke, Leicester
Database management: James Thomas, Ellen Hill, nutritionist students,
Leeds; Jim Charvill, Chetan Ghandi, Leicester.
Funding: Food Standards Agency, United Kingdom, Grant contract No
T01032/33.
Competing interests: None declared.
Ethicalapproval:Obtained from the local ethics committees, Directorate of
Research and Development, Leicester and Leeds, LREC Ref 7260.
Participants gave signed informed consent before enrolment into the
study.
1 Mau G, Netter P. Are coffee and alcohol consumption risk factors in
pregnancy? [author’s translation]. Geburtshilfe Frauenheilkd
1974;34:1018-22.
2 Beaulac-Baillargeon L, Desrosiers C. Caffeine-cigarette interaction on
fetal growth. Am J Obstet Gynecol 1987;157:1236-40.
3 Fortier I,MarcouxS,Beaulac-BaillargeonL.Relationof caffeine intake
duringpregnancy to intrauterinegrowth retardationandpretermbirth
[see comment]. Am J Epidemiol 1993;137:931-40.
4 Vik T, Bakketeig LS, Trygg KU, Lund-Larsen K, Jacobsen G. High
caffeine consumption in the third trimester of pregnancy: gender-
specific effects on fetal growth. Paediatr Perinat Epidemiol
2003;17:324-31.
5 Eskenazi B, Stapleton AL, Kharrazi M, Chee WY, Eskenazi B,
StapletonAL,etal.Associationsbetweenmaternaldecaffeinatedand
caffeinated coffee consumption and fetal growth and gestational
duration. Epidemiology 1999;10:242-9.
6 Martin TR,BrackenMB.Theassociationbetween lowbirthweightand
caffeine consumption during pregnancy. Am J Epidemiol
1987;126:813-21.
7 Fenster L, Eskenazi B,WindhamGC, SwanSH. Caffeine consumption
during pregnancy and fetal growth. Am J Public Health
1991;81:458-61.
8 Peacock JL, Bland JM, Anderson HR. Effects on birthweight of alcohol
and caffeine consumption in smoking women. J Epidemiol
Community Health 1991;45:159-63.
9 Vlajinac HD, Petrovic RR, Marinkovic JM, Sipetic SB, Adanja BJ. Effect
of caffeine intake during pregnancy on birth weight. Am J Epidemiol
1997;145:335-8.
10 Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG,
Ryan KJ. No association between coffee consumption and adverse
outcomes of pregnancy. N Engl J Med 1982;306:141-5.
11 CookDG,Peacock JL, FeyerabendC,Carey IM, JarvisMJ, AndersonHR,
et al. Relation of caffeine intake and blood caffeine concentrations
during pregnancy to fetal growth: prospective population based
study. BMJ 1996;313:1358-62.
12 Committee on Toxicity. COT statement on the reproductive effects of
caffeine. London: Committee on Toxicity of Chemicals in Food,
Consumer Products and the Environment, 2001. http://cot.food.gov.
uk/cotstatements/cotstatementsyrs/cotstatements2001/caffeine
13 Grosso LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B,
Bracken MB, et al. Maternal caffeine intake and intrauterine growth
retardation. Epidemiology 2001;12:447-55.
14 Clausson B, Granath F, Ekbom A, Lundgren S, Nordmark A,
Signorello LB, et al. Effect of caffeine exposure during pregnancy on
birth weight and gestational age. Am J Epidemiol 2002;155:429-36.
15 Bracken MB, Triche EW, Belanger K, Hellenbrand K, Leaderer BP.
Association of maternal caffeine consumption with decrements in
fetal growth. Am J Epidemiol 2002;155:429-36.
16 Santos IS, Victora CG, Huttly S, Carvalhal JB, Santos IS, Victora CG,
et al. Caffeine intake and low birth weight: a population-based case-
control study. Am J Epidemiol 1998;147:620-7.
17 Weathersbee PS, Olsen LK, Lodge JR. Caffeine and pregnancy-
retrospective survey. Postgrad Med 1977;62:64-5.
18 Srisuphan WBM. Caffeine consumption during pregnancy and
association with late spontaneous abortion. Am J Obstet Gynecol
1986;154:14-20.
19 Goldstein A, Warren R. Passage of caffeine into human gonadal and
fetal tissue. Biochem Pharmacol 1962;11:166-8.
20 Kirkinen P, Jouppila P, Koivula A, Vuori J, Puukka M. The effect of
caffeine on placental and fetal blood flow in human pregnancy. Am J
Obstet Gynecol 1983;147:939-42.
21 AldridgeA,ArandaJV,NeimsAH.Caffeinemetabolisminthenewborn.
Clin Pharmacol Ther 1979;25:447-53.
22 Rasmussen BB, Brix TH, Kyvik KO, Brøsen K. The interindividual
differences in the 3-demethylation of caffeine alias CYP1A2 is
determined by both genetic and environmental factors.
Pharmacogenetics 2002;12:473-8.
23 Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD,
Josephs H. The caffeine CO2 breath test: dose response and route of
N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther
1982;32:261-9.
24 KalowW,TangBK.UseofcaffeinemetaboliteratiostoexploreCYP1A2
and xanthine oxidase activities. Clin Pharmacol Ther
1991;50:508-19.
25 Grosso LM, Triche EW, Belanger K, Benowitz NL, Holford TR,
Bracken MB. Caffeine metabolites in umbilical cord blood,
cytochrome P-450 1A2 activity, and intrauterine growth restriction.
Am J Epidemiol 2006;163:1035-41.
26 Boylan SM, Cade JE, Kirk SFL, Greenwood DC, White KLM, Shires S,
et al. Assessing caffeine exposure in pregnant women. Br J Nutr
2008, Online publication doi:10.1017/S0007114508939842.
27 Directorate MFS. Survey of caffeine and other methylxanthines in
energydrinksandothercaffeine-containingproducts (updated).Food
Surveillance Information Sheet 1998:144.
28 Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al.
Determination of Cyp1a2 and Nat2 phenotypes in human-
populations by analysis of caffeine urinary metabolites.
Pharmacogenetics 1992;2:116-27.
29 Binnie V, McHugh S, Macpherson L, Borland B, Moir K, Malik K. The
validationofself-reportedsmokingstatusbyanalysingcotinine levels
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 8
in stimulated and unstimulated saliva, serum and urine. Oral
Diseases 2004;10:287-93.
30 Gardosi J. Customised fetal growth standards: rationale and clinical
application. Semin Perinatol 2004;28:33-40.
31 BrownMA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM.
The classification and diagnosis of the hypertensive disorders of
pregnancy: Statement from the International Society for the Study of
Hypertension in Pregnancy (ISSHP). Hypertension in Pregnancy
2001;20:IX-XIV.
32 Stata statistical software: Release 10. College station, TX: Stata
Corporation, 2007.
33 Weng X, Odouli R, Li DK. Maternal caffeine consumption during
pregnancyand the riskofmiscarriage:aprospectivecohort study.Am
J Obstet Gynecol 2008;198:279 e1-8.
34 RosenbergL,MitchellAA,ShapiroS,SloneD.Selectedbirthdefects in
relation to caffeine-containing beverages. JAMA 1982;247:1429-32.
35 Organisation of Teratology Information Specialists. Caffeine and
pregnancy. December, 2006. www.otispregnancy.org
36 BrackenMB, Triche E, Grosso L, Hellenbrand K, Belanger K, Leaderer,
et al. Heterogeneity in assessing self-reports of caffeine exposure:
implications for studies of health effects. Epidemiology
2002;13:165-71.
37 Bech BH, Obel C, Henriksen TB, Olsen J. Effect of reducing caffeine
intakeonbirthweightand lengthofgestation: randomisedcontrolled
trial. BMJ 2007;334:409-12.
38 Bicalho GG, Barros Filho Ade A. [Birthweight and caffeine
consumption]. Revista de Saude Publica 2002;36:180-7.
39 Klebanoff MA, Levine RJ, Dersimonian R, Clemens JD, Wilkins DG.
Serum caffeine and paraxanthine as markers for reported caffeine
intake in pregnancy. Ann Epidemiol 1998;8:107-11.
40 Klebanoff MA, Levine RJ, Clemens JD, Wilkins DG. Maternal serum
caffeine metabolites and small-for-gestational age birth. Am J
Epidemiol 2002;155:32-7.
41 Klebanoff MA, Levine RJ, DerSimonian R, Clemens JD, Wilkins DG.
Maternal serum paraxanthine, a caffeine metabolite, and the risk of
spontaneous abortion. N Engl J Med 1999;341:1639-44.
Accepted: 24 October 2008
RESEARCH
page 8 of 8 BMJ | ONLINE FIRST | bmj.com
